Tirzepatide After Weight Loss: What SURMOUNT-4 Means for Long-Term Budgeting

01A withdrawal trial starts with a different question

SURMOUNT-4 was a phase 3 trial conducted at 70 sites in four countries. Eligible adults had a body mass index, or BMI, of at least 30, or at least 27 with a weight-related complication. Diabetes was excluded. Everyone entering the lead-in received once-weekly subcutaneous tirzepatide—an injection under the skin—with diet and physical activity. The reported maximum tolerated doses were 10 or 15 mg; these identify study treatment, not instructions for individual use.

The first 36 weeks were open-label, meaning participants and investigators knew treatment was being given. Only afterward did the double-blind, placebo-controlled comparison begin. Random allocation helps separate the effect of continuing tirzepatide from other influences during maintenance because both groups had already experienced active treatment. It does not provide a randomized comparison of starting tirzepatide versus never taking it, and the initial 20.9% loss should not be read as that kind of comparison.

02Why 783 and 670 are not interchangeable

Of 783 participants entering the lead-in, 670 reached randomization: 335 continued tirzepatide and 335 switched to placebo for 52 weeks. The difference is 113 people, or approximately 14.4% of those initially enrolled. The indexed abstract does not give a complete breakdown of why they did not enter randomization. It would therefore be incorrect to label all 113 as adverse-event withdrawals, treatment failures, or people who could not afford treatment.

The randomized population nevertheless reflects selection through 36 weeks of treatment and tolerability assessment. Its mean age was 48 years, 71% were women, and the report gives a mean weight of 107.3 kg. Results most directly describe people who reached this maintenance decision point, not everyone considering a first injection. This selected-tolerator design is valuable for the continuation question, while leaving more uncertainty about outcomes among people who discontinue early or cannot tolerate the studied treatment.

03Two baselines explain the seemingly conflicting percentages

The primary endpoint was mean percentage weight change from week 36, when randomization occurred, to week 88. Continued tirzepatide produced an additional 5.5% reduction relative to week-36 weight; placebo produced a 14.0% increase relative to that same later baseline. By contrast, the reported overall losses of 25.3% and 9.9% compare week 88 with the original week-0 starting weight. Those results are compatible because their denominators differ.

An illustrative calculation makes the distinction concrete. Starting with 100 weight units, a 20.9% reduction leaves 79.1. A further 5.5% reduction from 79.1 leaves about 74.7; a 14.0% increase from 79.1 leaves about 90.2. These approximate the reported overall results, but are not reconstructed participant-level estimates. Group averages and rounding prevent exact identity. Simply adding −20.9% and +14.0% would incorrectly treat the two changes as if they shared a baseline.

04The treatment difference is large, but it is not a risk reduction

The report estimated a between-group difference of −19.4 percentage points in weight change, with a 95% confidence interval from −21.2 to −17.7. The displayed group means differ by 19.5 points; rounding and the reported estimation can explain why subtracting the printed values does not exactly reproduce the reported difference. The confidence interval describes uncertainty around the estimated average contrast under the analysis, not the range within which individual participants’ weight changes necessarily fell.

This endpoint measures weight change, not the probability of a cardiovascular event, death, or another clinical outcome. Calling it a 19.4% reduction in health risk would change its meaning. Nor does the clear difference establish a guaranteed result for an individual. Our separate SURMOUNT-5 head-to-head analysis addresses a different comparison; a randomized withdrawal study cannot rank tirzepatide against another active medicine.

05Maintaining 80% of a loss does not mean losing 80% of body weight

A key secondary endpoint asked whether participants retained at least 80% of the weight they had lost during the lead-in. For illustration, someone who had lost 20 weight units would meet that threshold if at least 16 units remained lost at follow-up. The threshold allows some regain, and it does not require further weight reduction. In SURMOUNT-4, 300 participants receiving continued tirzepatide, or 89.5%, met it, compared with 16.6% receiving placebo.

The absolute difference was 72.9 percentage points in the proportion meeting this specific maintenance definition. That complements the average weight-change endpoint by showing how often a meaningful retention threshold was achieved. It still does not reveal every participant’s trajectory, identify who will maintain weight after withdrawal, or establish that everyone in the placebo group regained all lost weight. Indeed, that group remained an average of 9.9% below its original weight at week 88.

06Gastrointestinal effects remain part of the maintenance evidence

SURMOUNT-4 reported gastrointestinal adverse events as the most common adverse events. They were mostly mild to moderate and occurred more frequently with tirzepatide than placebo. Those findings matter even after participants have passed through an initial treatment period. A maintenance benefit does not mean continuing treatment is free of symptoms or acceptable to every person.

The indexed abstract does not provide detailed event rates, serious-event counts, or a complete accounting of discontinuations by cause. That limits a numerical benefit-harm comparison from this evidence packet. Selection into the randomized phase also means its tolerability experience cannot substitute for the experience of everyone who starts treatment. NIDDK frames duration around benefit and tolerability, alongside health history, other medicines, adverse effects, and cost—not weight change alone.

07SURMOUNT-MAINTAIN tested more than continuation versus stopping

It is no longer accurate to say there is no maintenance-dose research. The newer 2026 SURMOUNT-MAINTAIN report describes a phase 3b trial at 20 US sites lasting 112 weeks. After 60 weeks of open-label, once-weekly subcutaneous tirzepatide at a maximum tolerated 10 or 15 mg dose, participants were randomized to continue that treatment, enter a 5 mg arm, or switch to placebo for 52 weeks. These were study strategies, not a tested self-directed tapering schedule.

There were 441 participants who enrolled and received treatment during the initial period, and 378 randomized at week 60: 140, 144, and 94 in the respective groups. Of those randomized, 345, or 91%, completed the study. The enrolled population had a mean age of 46.6 years, mean BMI of 40.1, and mean weight of 113.8 kg; 65% were female and 67% White. Eligibility included the specified BMI thresholds and a history of at least one self-reported unsuccessful dietary weight-loss effort.

The primary endpoint differed from SURMOUNT-4: it measured percentage weight change from the original baseline to week 112, not change only during the randomized maintenance period. Model-based estimates were −21.9% with maximum tolerated treatment, −16.6% with 5 mg, and −9.9% with placebo. Both active strategies outperformed placebo on that endpoint. The lower-dose strategy retained less average weight reduction than continued maximum tolerated treatment, but more than placebo.

08Rescue treatment changes how the newer trial should be read

Starting at week 84, 24 weeks after randomization, SURMOUNT-MAINTAIN allowed rescue tirzepatide when regain exceeded 50% of previously lost weight. The report lists rescue use in 11 of 138 participants in the maximum tolerated group, 35 of 142 in the 5 mg group, and 60 of 90 in the placebo group—approximately 8%, 25%, and 67%. Those observed denominators differ from the numbers randomized and should remain attached to the reported proportions.

Its primary estimand—the precise treatment effect the analysis sought to estimate—used a modified treatment-regimen approach. It included all randomized participants regardless of treatment discontinuation or prohibited medication use, while assuming no further benefit from assigned treatment after rescue began. Consequently, its placebo estimate is not a simple description of uninterrupted, untreated withdrawal for every participant. Gastrointestinal events were again the most common adverse events with tirzepatide, mostly mild to moderate and mostly occurring during escalation. Eli Lilly funded the study.

09Semaglutide withdrawal supports the pattern, not an interchangeable estimate

The STEP 1 extension followed 327 participants after the original semaglutide trial. In this subset, mean loss during 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg was 17.3%. Over the subsequent year, participants regained 11.6 percentage points relative to original baseline weight, leaving a net 5.6% loss at week 120. The approximately two-thirds regain describes this group average, not a universal personal outcome. Our STEP 1 regain analysis examines that evidence separately.

Unlike SURMOUNT-4, this was an exploratory off-treatment extension, not a new randomization to continuation versus withdrawal. Both medication and structured lifestyle intervention stopped at week 68. Some cardiometabolic improvements moved toward baseline, although not every measure lost all improvement. Adverse events were not systematically collected during the extension. Novo Nordisk funded STEP 1. Different drugs, selection processes, support arrangements, and baselines prevent using these studies as a head-to-head comparison or as a single pooled prediction of regain.

10A maintenance horizon is not an economic analysis

Editorial interpretation: the trials make a short introductory price an incomplete basis for planning. They measured a year of randomized maintenance after substantial lead-in treatment, not whether a household could sustain payments. Neither tirzepatide abstract supplies subscription charges, insurance continuity, cost per maintained kilogram, or lifetime cost-effectiveness. A budget built from a written quote and a check of billing-cycle definitions address financial questions the trials did not measure.

Editorial interpretation: clinical continuation and a commercial renewal are separate decisions. Cancellation and refund terms deserve documentary review without treating cancellation policy as medical guidance. Readers comparing services can use the CoreAge Rx review to check written pricing and contract terms; that link does not establish access to the studied product, condition-specific care, or trial-like outcomes. NIDDK also notes that coverage varies and clinical results are not insurance promises.

A cheaper formulation cannot inherit the evidence by price comparison. FDA states that compounded drugs are not FDA approved or reviewed before marketing for safety, effectiveness, or quality, and identifies concerns including dosing errors and semaglutide salt ingredients. Reports alone cannot establish event rates or causation. The guide to compounded and approved pricing keeps that distinction explicit. These injection results do not automatically transfer to compounded preparations, oral routes, other formulations, or a provider’s service.

Questions & answers

Sources & documentation

Scientific and official sources consulted October 20, 2026. Study findings apply to the populations, products and time periods described; they are not provider outcome data.

1. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. ↗
2. NIDDK prescription medications for overweight and obesity ↗
3. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. ↗
4. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. ↗
5. FDA concerns about unapproved GLP-1 drugs ↗

Continue reading

• After Semaglutide Stops: What STEP 1 Weight Regain Means for Long-Term Budgeting
• SURMOUNT-5: What a Direct Weight-Loss Comparison Can—and Cannot—Tell Your Budget
• Build a GLP-1 Budget From Your Own Written Quote
• Monthly, Four-Week and Prepaid GLP-1 Billing Explained
• Canceling a GLP-1 Subscription: What Happens to the Money?
• Comparing Compounded and Approved GLP-1 Prices Responsibly